EB-1A杰出人才案例：生物技术博士后，研究癌症代谢调控机制，无RFE直接获批
EB-1A Extraordinary Ability Case: Biotech Postdoc Researching Cancer Metabolic Regulation — Approved Without RFE

一句话总结 (TL;DR)：新未名律所合伙人张媛媛律师代理一位生物技术（Biotechnology）博士后的EB-1A 杰出人才申请。申请人的研究方向为肿瘤及应激反应中的代谢与表观遗传调控机制，我们通过精准定位其研究对靶向癌症代谢治疗的重大价值，配合知名学者推荐信、高质量论文及广泛引用证据，于2026 年 1 月提交加急申请（Premium Processing），2 月即获批准，全程无 RFE（Request for Evidence）补件。如果您是美国首都华盛顿地区从事生物医药或基础科研的博士/博士后，正在寻找靠谱华人移民律师办理 EB-1A，本案例值得参考。

TL;DR: New Weiming Law Group Partner Attorney Yuanyuan Zhang successfully handled an EB-1A Extraordinary Ability petition for a biotechnology postdoctoral researcher specializing in metabolic and epigenetic regulation in cancer and stress responses. By strategically framing the applicant's contributions to targeted cancer metabolism therapy, supported by strong recommendation letters from renowned scholars, high-impact publications, and extensive citations, the petition was filed with Premium Processing in January 2026 and approved in February 2026 — with no RFE.

案例背景是什么？ | What Is the Background of This Case?

本案由新未名律所合伙人张媛媛律师（yuanyuan.zhang@nwmlaw.com）主办。申请人拥有生物技术（Biotechnology）博士（Ph.D.）学位，目前在一所研究机构担任博士后研究员（Postdoctoral Researcher），持J-1 或 H-1B 等工作签证在美从事科研工作。

This case was led by New Weiming Law Group Partner Attorney Yuanyuan Zhang. The applicant holds a Ph.D. in Biotechnology and is currently working as a postdoctoral researcher at a U.S. research institution. His primary research focus is on themetabolic and epigenetic regulatory mechanisms underlying cancer and stress responses.

申请人的研究方向有何特殊价值？ | What Makes the Applicant's Research Significant?

申请人的核心研究领域是肿瘤及应激反应中的代谢与表观遗传调控机制（Metabolic and Epigenetic Regulation in Cancer and Stress Responses）。代谢重编程（metabolic reprogramming）和表观遗传改变（epigenetic alterations）是当今癌症研究最前沿的方向之一，直接关系到新一代靶向癌症代谢治疗（targeted cancer metabolism therapy）的开发。

The applicant's work sits at the intersection of cancer biology, metabolic reprogramming, and epigenetics — areas that are critical to developing next-generation targeted therapies for cancer treatment. Understanding how tumor cells rewire their metabolic pathways and how epigenetic mechanisms regulate stress responses can lead to breakthrough therapeutic strategies.

律所采取了怎样的申请策略？ | What Strategy Did New Weiming Law Group Employ?

在准备 EB-1A（杰出人才，Extraordinary Ability）I-140 申请过程中，新未名律所团队采取了以下核心策略：

• 精准研究定位（Research Framing）：将申请人的基础科研成果与靶向癌症代谢治疗的转化价值紧密关联，向移民官清晰呈现其研究的实际意义和社会影响力（National and International Impact）。
  Strategically framed the applicant's basic research in the context of targeted cancer metabolism therapy, demonstrating clear translational value and societal impact.
• 高质量推荐信（Recommendation Letters）：获得多位国际知名学者（Distinguished Scholars）的独立推荐信，从不同角度佐证申请人的原创贡献和学术领域地位。
  Secured strong independent recommendation letters from internationally recognized scholars to corroborate the applicant's original contributions and standing in the field.
• 论文与引用策略（Publications & Citations）：系统整理申请人的高质量期刊论文、会议论文及广泛的他引数据（citation evidence），展示其研究成果被同行认可和广泛采用的事实。
  Systematically presented the applicant's high-impact publications and extensive citation records to demonstrate peer recognition and the widespread adoption of the research.
• 加急审理（Premium Processing）：申请于2026 年 1 月提交时选择了加急处理（15 个日历日内出结果），2 月即获直接批准。
  Filed with Premium Processing in January 2026; the petition was approved in February 2026 within the expedited timeline.

为什么能做到无RFE直接获批？ | Why Was the Case Approved Without an RFE?

RFE（Request for Evidence，补件通知）是移民局在审理 EB-1A 等职业移民申请时常见的步骤。能够做到无 RFE 一次性通过，通常意味着申请材料在证据组织、法律论证、研究叙事三方面都达到移民官的举证标准。本案中，我们通过以下要点实现了"零RFE"结果：

• Petition Letter（申请信）逻辑严密，直接回应 EB-1A 十条标准中申请人所满足的多个条件，包括但不限于：发表高质量学术论文（Authorship of Scholarly Articles）、被广泛引用（Evidence of Citations）、获得行业知名学者的认可（Judging / Peer Review）、以及在本领域做出原创性重大贡献（Original Contributions of Major Significance）。
• 每一项主张都附有充分的佐证材料和具体数据，不给移民审查官留下质疑空间。
• 推荐信的撰写在内容深度和细节层面与申请信的论证互相呼应，形成闭环式（closed-loop）证据链。

Achieving ano-RFE approval in an EB-1A case reflects the thoroughness of the evidentiary record. Our Petition Letter directly addressed multipleEB-1A criteria — including authorship of scholarly articles in major publications, significant citation metrics, peer review activities, and original contributions of major significance. Each claim was supported by concrete data and corroborating materials, and the recommendation letters provided a consistent, reinforcing narrative.

哪些人适合参考这个EB-1A案例？ | Who Can Benefit from This EB-1A Case Study?

如果您属于以下情况之一，这个成功案例对您可能特别有参考价值：

• 持有 F-1/J-1/H-1B/O-1 签证，在美国高校或研究机构从事生物医学、生物技术、癌症研究、分子生物学等领域科研的博士后或研究员。
• 拥有高质量 SCI/SSCI 期刊论文但不确定引用量是否"够格"申请 EB-1A 的科研人员。
• 正在考虑 EB-1A 与NIW（国家利益豁免） 双申策略（Dual Filing）以最大化获批概率的申请人。
• 身处大华府DMV地区（马里兰(Maryland)、弗吉尼亚(Virginia)、华盛顿特区）的NIH、FDA、约翰霍普金斯、乔治城大学等机构的华人科研人员和留学生。
• J-1 签证面临两年回国服务要求（Two-Year Home Residency Requirement），需要先办理 J-1 豁免（J-1 Waiver）再走 EB-1A 或 NIW 绿卡的申请人。

If you are a postdoctoral researcher or scientist working in biomedical sciences, biotechnology, cancer biology, molecular biology, or related fields in the Washington D.C. metropolitan area (DMV — Maryland, Virginia, D.C.), and you are considering EB-1A, NIW (National Interest Waiver), or a dual-filing strategy, this case study is particularly relevant. Researchers at NIH, FDA, Johns Hopkins, Georgetown University, University of Maryland, and similar institutions are encouraged to reach out for a free evaluation.

EB-1A与NIW可以同时申请吗？ | Can I FileEB-1A and NIW Simultaneously?

可以。许多科研人员选择 EB-1A +EB-2 NIW 双申策略。EB-1A 属于职业移民第一优先类别（EB-1），排期通常更快甚至当前无排期；NIW 属于 EB-2 类别，虽然排期（Priority Date）可能较长，但举证门槛相对更灵活。两者可同时递交 I-140 申请，互不影响。如果您同时满足两类条件，双申可以最大化您获得绿卡的效率和安全冗余。新未名律所在EB-1A 和 NIW 双申策略方面有大量成功案例。

Yes. Many researchers adopt a dual-filing strategy (EB-1A + EB-2 NIW). EB-1A falls under the first employment-based preference category and often has shorter or no visa backlogs; NIW falls under EB-2, which may have a longer priority date queue but offers a more flexible evidentiary standard. Both I-140 petitions can be filed simultaneously.New Weiming Law Group has extensive experience helping clients execute this strategy successfully.